Porphyrin Derivatives and Photodynamic Therapy Effects on Triple Negative Breast Cancer by Rogers, Sarah et al.
Ouachita Baptist University
Scholarly Commons @ Ouachita
Scholars Day Carl Goodson Honors Program
2015
Porphyrin Derivatives and Photodynamic Therapy







Follow this and additional works at: http://scholarlycommons.obu.edu/scholars_day
Part of the Biology Commons, Chemistry Commons, and the Diseases Commons
This Poster is brought to you for free and open access by the Carl Goodson Honors Program at Scholarly Commons @ Ouachita. It has been accepted
for inclusion in Scholars Day by an authorized administrator of Scholarly Commons @ Ouachita. For more information, please contact
mortensona@obu.edu.
Recommended Citation
Rogers, Sarah; Bradshaw, Joseph E.; and Hayes, Timothy E., "Porphyrin Derivatives and Photodynamic Therapy Effects on Triple
Negative Breast Cancer" (2015). Scholars Day. Paper 2.
http://scholarlycommons.obu.edu/scholars_day/2
 Porphyrin Derivatives and Photodynamic Therapy Effects on Triple Negative Breast Cancer  
*Sarah Rogers1, Joseph E. Bradshaw, PhD2 and Timothy E. Hayes, PhD2 
Departments of Biology1 and Chemistry2, Ouachita Baptist University 




   
Materials and Methods	

Cell culture- MDA-MB 231 TNBC cells were grown using 
published protocols.  For each experiment, two sets of 96-
well plates were needed- one exposed to light and one kept 
in the dark.  Varying concentrations of porphyrins were 
applied to the wells in growth medium in the dark, and the 
plates were returned to the 37°C incubator.  8 wells were 
used for each condition.  After 24 hours, medium from both 
plates was replaced with fresh culture medium.  One plate 
of cells was exposed to white light at (0.5 J/cm²) and both 
plates were cultured in the dark for 3 days at 37°C.  An MTT 
assay for cell proliferation was performed on the TNBC cells 
and absorbance was read on a microplate reader at a 570 
nm wavelength with a 630 nm correction.  Values from 
replicate wells were used to calculate the average and 
standard deviation.  % viability was calculated by 
comparison to the average of the untreated wells. 
Light dose- 4 plates were grown with cells and treated 
identically with different porphyrin concentrations.  After 24 
hours, medium with porphyrin was removed from the cells 
and replaced with fresh growth medium.  3 of the plates 
were exposed to varying amounts of light- 0.5, 5, or 15 J/
cm²- and returned to the 37°C incubator for 3 days in the 
dark.  An MTT assay was performed on the 96-well plates 
to measure viability.  
Uptake- Two 24-well plates were prepared, one with cells 
and a parallel plate with no cells, to be treated with 
porphyrins.  Porphyrins were diluted into fresh growth 
medium supplemented with 0.01% BSA.  0.5 ml of each 
dilution was added to each of 6 wells-3 wells with and 3 
wells without cells.  The plates were incubated at 37°C in 
the dark.  After 24 hours, medium was aspirated from the 
wells and the cells washed 2x with 1ml of PBS.  250 µl of 
0.25% Triton X 100 in PBS was added to each well and 
then incubated at 37°C in the dark.  After 1 hour, the plates 
were shaken for 15 minutes at room temperature.  200 µl 
was removed from each well and transferred to a clean, 
labeled tube.  The tubes were centrifuged for 3 minutes at 
16,000 x g.  A fluorescence assay was performed on 
aliquots of the supernatant, and the remainder of the 
samples was frozen until the protein assay.  A standard 
curve was prepared by diluting a porphyrin standard 
solution into 0.25% Triton X 100 in PBS. The fluorescence 
of each dilution was measured by exciting the wells at 415 
nm and reading the emission at 650 nm. The standard 
curve was used to find the amount of porphyrin in each well.  
Protein assays were performed on the supernatants using 
the Bradford protocol.   
Goal- To find a better treatment method for triple negative 
breast cancer. 
Objectives:  
•  Measure how well the porphyrin derivatives are taken up 
by TNBC cells 
•  Find a combination of light dose and porphyrin 
concentration that kills cells at higher doses of light but 




There are limited effective options for treatment of triple negative 
breast cancer (TNBC) due to its lack of the three receptors 
typically used to target breast cancer.  The use of photodynamic 
therapy (PDT) to kill cells that take up light-absorbing 
compounds (PDT agents) may be an effective option to treat 
TNBC.  We tested the efficacy of modified porphyrins as PDT 
agents against cells from TNBC.  We compared these to Foscan, 
which is similar in structure to porphyrins and has been approved 
for use in Europe.  Our 1st goal was to measure which porphyrins 
were taken up best by TNBC cells.  Measuring the uptake of 
some of our compounds had been problematic due to their 
hydrophobic nature.  We optimized the uptake protocol and 
showed that TNBC cells take up the compounds to different 
extents.  One of the primary side effects of PDT is skin toxicity 
for up to 4-6 weeks after treatment due to exposure to sunlight.  
Our 2nd goal was to compare the toxicity in the light and in the 
dark of PipOH, H2TPPC, and Foscan.  In previous experiments, 
Foscan showed dark toxicity at low concentrations, but in these 
experiments there was variability in our results with Foscan so 
no clear comparison could be drawn.  Our 3rd goal was to find 
combinations of PDT agent and concentration that are effective 
on TNBC cells at high light energy but minimize killing cells with 
ambient light.  We measured the effect on cell killing by varying 
both the light dose and the concentration of 3 compounds to find 
concentrations that are effective at high doses of light but 
minimize toxicity at moderate doses.  All 3 compounds show 
promise, but the dose must be carefully selected. 
 There are limited effective options for treatment of 
triple negative breast cancer (TNBC) due to its lack of three 
receptors typically used to target breast cancer- the 
estrogen receptor, the progesterone receptor and the 
human epidermal growth factor receptor-2. The lack of 
these targets makes treatment difficult since patients with 
TNBC are not candidates for hormone therapy or 
trastuzumab-based regimens, which works on HER2. 
Current treatments for TNBC result in poor overall survival 
no matter the stage with a rapid increase in the risk of 
recurrence at 1-3 years. Better treatment options are 
essential to ensure better treatment and survival rates. 
People of younger age, African American race, younger age 
at menarche, strong family link to breast cancer, and those 
with breast cancer 1 early onset (BRCA1) mutation are at 
an increased risk for developing TNBC.   
 Photodynamic therapy (PDT) is a form of therapy 
used to kill tumors.  A photosensitizer (PS) is applied to the 
area of treatment. Exposing the PS to light produces a 
reaction with oxygen that kills both tumors and vasculature. 
Foscan is a PS that has been approved for use in Europe 
and is highly effective for some types of tumors. Use of this 
drug necessitates that patients stay in the dark for 24 hours 
after treatment because exposure to ambient light may 
cause burns. One purpose of the current study is to find a 
combination of porphyrin concentration and light dose that 
minimizes the unwanted side effects of skin sensitivity.   
 One of the properties that determine how active a 
PDT agent will be is how well it is taken up by cells. 
Transport in the blood and uptake by cells require a balance 
between the hydrophilic and hydrophobic nature of the 
porphyrins.  We have had difficulty measuring uptake of 
some porphyrins because they stick to the plastic plates 
used to grow the cells. To accurately measure uptake, it is 
important to find methods to reduce background binding.   
Introduction	

Porphyrins- the porphyrins used in this research were 
synthesized in the lab of Joe Bradshaw.  PipOH, H2TPPC, 
and H2TPPSO were made by adding different side chains 
with varying hydrophobic and hydrophilic properties to the R 
positions of the porphyrin ring structure.  Foscan has a 
chlorin ring which is similar to the porphyrin ring except that 
one of the C=C double bonds in one of the pyrrole rings is 
reduced to a single bond. 
 























Figure 2. Reagents to reduce background 
binding.  Detergents (Triton X100- 0.004%, NP-40- 
0.001%, SDS- 0.01%) and proteins (BSA- 0.01%, Gelatin- 
0.01%) were mixed in growth medium before porphyrin 
was added. Parallel plates, one with MDA-MB 231 TNBC 
cells and one without cells, were treated with the porphyrin 
solutions (3 wells per condition) for 24 hours and uptake 
was measured. Error bars indicate standard deviations. 
 Results- Some reagents produced a significant 
increase in binding to the cells compared to the wells. BSA 
appeared to have the greatest effect.  It is possible that the 
reagents increase specific binding by reducing aggregation 
of the hydrophobic porphyrin derivatives. 
 Uptake: For some porphyrins, binding to cells was a 
modest fraction of total binding in uptake experiments.  Two 
methods were tried to increase the ratio of the specific 
binding versus background binding of the porphyrin to the 
plastic wells. Pre-treating the wells with detergents or 
proteins before cells were added was not effective (data not 
shown). The second method we tried was mixing 
detergents or proteins with growth medium before adding 
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 We were able to overcome low specific binding of 
PipOH to cells by adding BSA to the growth medium prior to 
adding the PipOH.  This enabled us to measure affinity of 
PipOH for TNBC cells.  Additional experiments are 
underway to measure the uptake of Foscan and H2TPPC.   
We are unsure the exact extent to which Foscan is taken up 
by the cells, but we do know that it is taken up much better 
than any other porphyrin we have tested so far. Our results 
from the light dose experiment seem promising in finding a 
combination of light dose and porphyrin concentration that 
minimize unwanted skin toxicity from ambient light.  At 10 
nM, Foscan shows high viability up to 5 J/cm2 , but 
significant toxicity at 15 J/cm2.  PipOH and H2TPPSO show 
a similar pattern but have less separation between viability 
at moderate and higher doses of light.  Higher doses of light 
in the clinical range of 50-200 J/cm2  need to be tested.   
 Figure 8. Effect of light dose on viability at varying 
concentrations of PipOH and H2TPPSO (average of three 
experiments). 
 Results- There are concentrations of both PipOH (0.3 
µM) and H2TPPSO (1 µM) which show fairly high viability at 
light doses up to 5 J/cm2 but increased toxicity at 15 J/cm2.  
However, both show similar toxicity at 5 J/cm2 or lower 
toxicity at 15 J/cm2 than does 10 nM Foscan. 
 Light Dose- MDA-MB 231 TNBC cells were grown 
on 4 96-well plates for 3 days before treating with varying 
concentrations of porphyrin. After incubation for 24 hours, 
the plates were exposed to varying light doses (0.5, 5, and 
15 J/cm²) with 1 plate kept in the dark.  After 3 more days, 
wells were assayed for viability using an MTT assay. 
 Figure 7. Effect of light dose on viability at varying 
concentrations of Foscan (average of three experiments).  
 Result- At 10 nM, Foscan shows high viability up to 5 
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Figure 1. Porphyrin structures.   
 MTT assay- In the MTT assay, viable cells oxidize 
the water-soluble yellow MTT to a purple insoluble 
formazan.  The purple precipitate is dissolved in DMSO and 
quantitated by absorbance.  More purple color indicates 
more viable cells. 
 Figure 5- A 96-well plate showing variances in 
purple color indicating differences in cell viability.  
 Figure 6- Effects of porphyrin concentration on TNBC 
cell viability in the dark and with exposure to light. 
 Results- Foscan shows concentration-dependent 
killing of TNBC cells if they are exposed to light.  In the 














































 Figure 3. Dependence of PipOH uptake on 
concentration.  0.01% BSA was mixed into growth medium 
before porphyrin was added. Medium with porphyrin was 
added to parallel plates, one with MDA-MB 231 TNBC cells 
and one without cells (3 wells per condition).  After 24 hours 
of incubation, PipOH uptake was assayed by fluorescence, 
and protein assays were performed on the dissolved cells. 
Standard deviations from triplicate wells are shown by error 
bars.   
 Results- As the concentration of PipOH increases, 
the amount of porphyrin taken up by the cells increases in a 
linear fashion. Most of the binding is to the cells. The slope 
of the regression line is a measure of the affinity of binding. 
The affinity of PipOH is similar to but slightly better than that 
of the previously tested porphyrins (see Table I). 
 Table 1. Specific binding of porphyrins to MDA-MB  
231 TNBC cells. 
       Specific Binding 
Porphyrin         (fmoles/ug/uM) 
PipOH                 9.4   
PipEtOH                 6.8   
APDIPA                  3   
H2TPPSO                 2.5   
Foscan             138-459   
